Synergy Pharmaceuticals, Inc. (SGYP) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
420 LEXINGTON AVENUE NEW YORK, NY 10170 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2018 MRQ | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 136,986 | 82,387 | 111,750 | 196,367 | 68,157 | 32,502 | |||
| Cash and cash equivalent | 136,986 | 82,387 | 61,653 | 146,470 | 18,130 | 12,416 | |||
| Short-term investments | 50,097 | 49,897 | 50,027 | 20,086 | |||||
| Receivables | 6,491 | ||||||||
| Inventory, net of allowances, customer advances and progress billings | 17,214 | 5,640 | ✕ | ✕ | |||||
| Inventory | 17,214 | 5,640 | |||||||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 1,547 | ||
| Other undisclosed current assets | 4,469 | 889 | 3,305 | 3,836 | 3,718 | ||||
| Total current assets: | 165,160 | 88,916 | 115,055 | 200,203 | 71,875 | 34,049 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 1,134 | 593 | 531 | 642 | 589 | 30 | |||
| Long-term investments and receivables | 3,306 | ||||||||
| Due from related parties | 3,306 | ||||||||
| Deferred costs | 12,336 | ||||||||
| Other undisclosed noncurrent assets | 312 | 343 | 343 | 163 | 94 | 20 | |||
| Total noncurrent assets: | 1,446 | 936 | 874 | 13,141 | 683 | 3,356 | |||
| TOTAL ASSETS: | 166,606 | 89,852 | 115,929 | 213,344 | 72,558 | 37,405 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 38,147 | 29,430 | 19,579 | 18,331 | 15,676 | 7,315 | |||
| Interest and dividends payable | 233 | 294 | 1,988 | 2,500 | |||||
| Accounts payable | 23,256 | 15,584 | 13,263 | 13,869 | 13,542 | 5,255 | |||
| Accrued liabilities | 14,658 | 13,552 | 4,328 | 1,962 | 2,134 | 2,060 | |||
| Total current liabilities: | 38,147 | 29,430 | 19,579 | 18,331 | 15,676 | 7,315 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 98,660 | 22,665 | 151,241 | 200,000 | |||||
| Long-term debt, excluding current maturities | 98,660 | 22,665 | 151,241 | 200,000 | |||||
| Liabilities, other than long-term debt | 18,015 | 216 | 322 | 172 | 1,534 | 5,258 | |||
| Other liabilities | 433 | ||||||||
| Derivative instruments and hedges, liabilities | 17,582 | 216 | 322 | 172 | 1,534 | 5,258 | |||
| Other undisclosed noncurrent liabilities | 17,302 | ||||||||
| Total noncurrent liabilities: | 133,977 | 22,881 | 151,563 | 200,172 | 1,534 | 5,258 | |||
| Total liabilities: | 172,124 | 52,311 | 171,142 | 218,503 | 17,210 | 12,573 | |||
| Equity | |||||||||
| Equity, attributable to parent | (5,518) | 37,541 | (55,213) | (5,159) | 55,348 | 24,832 | |||
| Common stock | 25 | 20 | 11 | 11 | 10 | 7 | |||
| Additional paid in capital | 801,787 | 620,513 | 329,161 | 261,715 | 226,515 | 133,878 | |||
| Accumulated deficit | (807,330) | (582,992) | (384,385) | (266,885) | (171,177) | (109,053) | |||
| Total equity: | (5,518) | 37,541 | (55,213) | (5,159) | 55,348 | 24,832 | |||
| TOTAL LIABILITIES AND EQUITY: | 166,606 | 89,852 | 115,929 | 213,344 | 72,558 | 37,405 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2018 TTM | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 16,820 | |||||||
| Cost of revenue | (8,811) | |||||||
| Gross profit: | 8,009 | |||||||
| Operating expenses | (230,208) | (145,286) | (99,822) | (94,278) | (62,311) | (38,237) | ||
| Other undisclosed operating income | 2 | |||||||
| Operating loss: | (222,199) | (145,286) | (99,822) | (94,278) | (62,311) | (38,235) | ||
| Nonoperating income (expense) | (2,139) | (53,321) | (17,678) | (1,430) | 187 | (1,209) | ||
| Investment income, nonoperating | (2,464) | 59 | 218 | |||||
| Other nonoperating income | 121 | 83 | 506 | |||||
| Interest and debt expense | (1,209) | (6,921) | (4,566) | (2,911) | (21) | |||
| Loss from continuing operations: | (225,547) | (205,528) | (122,066) | (98,619) | (62,145) | (39,444) | ||
| Loss before gain (loss) on sale of properties: | (225,547) | (205,528) | (122,066) | (98,619) | (62,145) | (39,444) | ||
| Net loss attributable to parent: | (225,547) | (205,528) | (122,066) | (98,619) | (62,145) | (39,444) | ||
| Other undisclosed net income available to common stockholders, basic | 1,209 | 6,921 | 4,566 | 2,911 | 21 | |||
| Net loss available to common stockholders, diluted: | (224,338) | (198,607) | (117,500) | (95,708) | (62,124) | (39,444) | ||
Comprehensive Income ($ in thousands)
| 9/30/2018 TTM | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (225,547) | (205,528) | (122,066) | (98,619) | (62,145) | (39,444) | ||
| Comprehensive loss, net of tax, attributable to parent: | (225,547) | (205,528) | (122,066) | (98,619) | (62,145) | (39,444) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.